32. Prevention: Clinical 1054-05

1054-05 - EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

Session
1054 - Cardiovascular Disease Prevention: Learning from RCTs and Their Applications in Practice
Speakers
Pathway
32. Prevention: Clinical
Presentation Number
1054-05
Presentation Rating
 |